Aimed at increasing its footprint in cancer, Varian (NYSE:VAR) has agreed to acquire certain interventional oncology lines from Boston Scientific for $90M.
The portfolio of drug-loadable microsphere (Oncozene/Embozene Tandem) and bland embolic bead products (Embozene) are used to treat arteriovenous malformations and hypervascular tumors.
The products generated $21.2M in revenue in 2018.
Varian says the transaction will be immaterial to fiscal 2019 results and guidance but will be accretive to EPS in 2020.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.